Pharmaceuticals
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Pipeline
NanoViricides has completed a $6 million capital raise to fund development of its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Oncotelic and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics and Sapu Bioscience have published a landmark review establishing sub-15 nm nanoparticles as a breakthrough drug delivery platform capable of overcoming limitations of current therapies through enhanced tissue penetration and reduced toxicity.
Polypill Strategy Shows Promise for Heart Failure Treatment, Improving Outcomes and Medication Adherence
A new study demonstrates that a once-daily combination pill for heart failure patients significantly improves heart function, reduces hospitalizations, and enhances quality of life compared to traditional multi-pill regimens.
Study Finds Prasugrel May Offer Better Outcomes Than Ticagrelor for Diabetic Patients With Stents
New research presented at the American Heart Association's Scientific Sessions 2025 suggests prasugrel may be more effective than ticagrelor at preventing heart attacks, strokes, bleeding complications and death in diabetic patients who received coronary stents, challenging current interchangeable use of these antiplatelet medications.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Voyageur Pharmaceuticals Appoints Financial Veteran Virginia Alling to Board, Accelerating U.S. Market Strategy
Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling to its board of directors, strengthening its financial expertise to drive U.S. market expansion and capital market access for its pharmaceutical-grade barium and iodine contrast media products.
Jupiter Neurosciences Expands Brain Health Reach with Nugevia Supplement Line
Jupiter Neurosciences leverages its pharmaceutical expertise to launch Nugevia MND, a cognitive health supplement that addresses growing global demand for brain health solutions amid aging populations and represents a strategic bridge between clinical research and consumer wellness.
Cybin Inc. Announces Q2 2025 Financial Results and Business Update Conference Call
Cybin Inc. will host a conference call on November 13, 2025, to discuss its second-quarter financial results and provide updates on its late-stage neuropsychiatry pipeline, including breakthrough-designated psychedelic treatments for major depressive disorder and generalized anxiety disorder.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Quantumzyme Validates Sustainable Ibuprofen Manufacturing Process in Peer-Reviewed Publication
Quantumzyme Corp. has published research validating its enzymatic process for sustainable ibuprofen production, representing a significant advancement toward greener pharmaceutical manufacturing with reduced environmental impact.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Thomas Meier Appointed as New CEO of Medios AG, Signaling Strategic Growth Phase
Medios AG appoints Thomas Meier as new CEO to drive expansion in the European Specialty Pharma market, bringing international leadership experience from Swiss CDMO Bachem Holding AG.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
ABVC BioPharma Reports 230% Licensing Revenue Growth and Major Asset Expansion in Q3 2025
ABVC BioPharma achieved significant financial growth with 230% year-over-year licensing revenue increase and 181% asset expansion, driven by strategic investments in Taiwan manufacturing facilities that strengthen the company's global dual-core operational structure.
Quantum BioPharma Announces Private Placement to Strengthen Voting Control and Fund Operations
Quantum BioPharma Ltd. is conducting a $750 private placement that will significantly increase voting control for its key executives while providing working capital for its neurodegenerative and metabolic disorder treatments.
BIO CEO Warns U.S. Could Lose Biotech Leadership to China Within Two Years
GeoVax Labs calls for urgent policy action following Biotechnology Innovation Organization CEO John Crowley's warning that China could overtake U.S. biotech leadership within two years, highlighting the need for vaccine platform diversity, onshoring manufacturing, and protecting immunocompromised populations.
Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Phalanx Distribution Partnership
Voyageur Pharmaceuticals has signed a non-exclusive distribution agreement with Mexican company Phalanx to expand access to its barium-based contrast media products in Latin America, representing a strategic move to address growing demand for cost-effective medical imaging solutions in underserved markets.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
Soligenix ThermoVax Technology Addresses Critical Vaccine Stability Challenge in Epidemic Response
Soligenix's development of thermostable vaccines that remain stable at high temperatures could significantly reduce global vaccine wastage and improve deployment in outbreak regions where cold chain infrastructure is limited.
Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Submission Following Regulatory Feedback
Nutriband Inc. has received critical FDA guidance confirming the regulatory pathway for its AVERSA™ Fentanyl abuse-deterrent transdermal system, marking a significant step forward in addressing the opioid crisis through innovative pharmaceutical technology.
Nutriband Founder Returns as CEO to Lead Final Development of Abuse-Deterrent Fentanyl Patch
Nutriband founder Gareth Sheridan has resumed his role as CEO to lead the final development phase of AVERSA Fentanyl, an abuse-deterrent opioid patch with potential peak annual U.S. sales estimated between $80 million and $200 million.
NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference
NanoViricides will showcase its broad-spectrum antiviral drug platform at the upcoming PODD 2025 conference, highlighting progress toward Phase II trials for its lead candidate NV-387 targeting multiple respiratory viruses and MPox.
Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Soligenix's HyBryte Shows Promise as Potential First-Line Treatment for Cutaneous T-Cell Lymphoma
Soligenix Inc. is advancing HyBryte as a potential first-line therapy for early-stage cutaneous T-cell lymphoma following promising results from clinical trials that could reshape treatment standards in the rare disease space.
Datavault AI and Wellgistics Health Partner on Blockchain Drug Tracking System
Datavault AI and Wellgistics Health are collaborating to integrate blockchain technology into prescription drug tracking, aiming to improve transparency, efficiency, and patient safety in pharmaceutical distribution.
Nutriband's AVERSA Fentanyl Patch Advances Toward 2026 FDA Submission with $200M Market Potential
Nutriband Inc. is progressing with its abuse-deterrent fentanyl patch technology that could generate up to $800 million in annual sales while addressing the opioid crisis through tamper-resistant transdermal delivery.
Pentixapharm Restructures Operations with 50% Workforce Reduction to Focus on Advanced Clinical Programs
Pentixapharm Holding AG is implementing significant organizational changes including a 50% workforce reduction and reduced early-stage research to concentrate resources on its most advanced clinical development programs, particularly the Phase 3-ready CXCR4 program for treatment-resistant hypertension diagnosis.